API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
0
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
SP-3164 is an oral, next-generation molecular glue that uses deuterium-enabled chiral switching platform to stabilize the preferred (S)-enantiomer of avadomide, it has demonstrated clinical efficacy in non-Hodgkin Lymphomas and other hematologic malignancies.
Lead Product(s): SP-3164
Therapeutic Area: Oncology Product Name: SP-3164
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 11, 2023
Details:
SP-3164 is an oral, next-generation molecular glue that uses deuterium-enabled chiral switching platform to stabilize the preferred (S)-enantiomer of avadomide, it has demonstrated clinical efficacy in non-Hodgkin Lymphomas and other hematologic malignancies.
Lead Product(s): SP-3164
Therapeutic Area: Oncology Product Name: SP-3164
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 01, 2023
Details:
SP-3164 is an oral molecular glue that uses deuterium-enabled chiral switching platform to stabilize the S-avadomide, which has demonstrated encouraging single-agent and combination-therapy clinical efficacy in NHL and other hematologic malignancies.
Lead Product(s): SP-3164
Therapeutic Area: Oncology Product Name: SP-3164
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 27, 2023
Details:
SP-3164 is an oral, molecular glue that uses Salarius’ deuterium-enabled chiral switching platform to stabilize the preferred (S)-enantiomer of avadomide, that has demonstrated encouraging single-agent and combination-therapy efficacy in NHL and other hematologic malignancies.
Lead Product(s): SP-3164
Therapeutic Area: Oncology Product Name: SP-3164
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 19, 2023
Details:
SP-3164, an oral small molecule protein degrader has shown potent cereblon binding, efficient degradation of neosubstrates and induction of cell death in both lymphoma and multiple myeloma cells.
Lead Product(s): SP-3164
Therapeutic Area: Oncology Product Name: SP-3164
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 19, 2022
Details:
SP-3164 is a next-generation, deuterium-stabilized (S)-enantiomer of avadomide (CC-122), also a patent-protected new molecular entity derived from avadomide with the potential for increased efficacy and improved safety, based upon preclinical results to date.
Lead Product(s): SP-3164
Therapeutic Area: Oncology Product Name: SP-3164
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 11, 2022